Background: The bacterium Rhodococcus equi can cause severe pneumonia in foals.
| INTRODUCTION
Rhodococcus equi is a gram-positive bacterium that causes granulomatous pneumonia in foals, a widespread and costly disease for the equine industry. Treatment of R. equi pneumonia can be prolonged, have adverse effects for treated foals and their dams, 1 and contribute to development of antimicrobial resistance when antibiotics are used on a widespread basis. 2, 3 Thus, there is a great need for prevention of R. equi pneumonia. No commercially available vaccines against R. equi exist, 1, 4 such that prevention of pneumonia is based primarily on transfusion of plasma that is hyperimmune to R. equi (RE-HIP). 1, 5, 6 Transfusion of RE-HIP, however, is not completely effective in decreasing the incidence of R. equi pneumonia at horse breeding farms. 1, [7] [8] [9] [10] Clinical and randomized controlled trials have resulted in variable outcomes for the prophylactic efficacy of RE-HIP. [9] [10] [11] [12] [13] Efforts to identify more effective antigenic targets for preparing HIP are warranted.
The capsule-like polysaccharide, β-(1!6)-linked poly-N-acetylglucosamine (PNAG), is a highly conserved sugar molecule present on the surface of many pathogenic microbes including R. equi. 14 Recently, our laboratory has demonstrated that vaccinating pregnant mares protected their foals against experimental infection with R. equi when challenged at approximately 4 weeks of age. 15 Moreover, transfusion of plasma hyperimmune for PNAG (PNAG-HIP) protected additional foals against a similar experimental infection. 15 Although these findings indicate that PNAG is a valid target for immunizing donors to prepare PNAG-HIP, this study only compared foals transfused with standard non-HIP (SP) to those treated with PNAG-HIP 15 ; comparison of PNAG-HIP with RE-HIP was lacking. Protection against R. equi either by PNAG vaccination of mares or by transfusion of PNAG-HIP to foals was mediated by anti-PNAG antibodies that fix complement and mediate opsonophagocytic killing (OPK) by neutrophils in conjunction with complement. 15 Our objective was to better characterize the protection provided by PNAG-HIP relative to RE-HIP by comparing complement deposition and OPK of PNAG-HIP, RE-HIP, and SP in vitro.
| MATERIALS AND METHODS

| Plasmas and complement source
The following plasma products were used in this study: non-HIP (SP; 16 or whole R. equi. 4 For PNAG coating, plates were treated with 100 μL of PNAG, purified as described previously, 16 at 0.6 μg/mL and then incubated for a minimum of 3 hours. The strain of virulent R. equi used to coat plates (EIDL 5-331; confirmed virulent by polymerase chain reaction and in vivo infection 4, 15 ) was grown overnight in brain heart infusion broth (BHIB; Becton, Dickinson, and Co, Sparks, Maryland) at 37 C; 100 μL of a bacterial suspension prepared at an optical density (OD) of 1 (corresponding to a concentration of 1.0 × 10 8 R. equi/mL or 2.5 mg/mL of R. equi antigen) 4 at a 650-nm wavelength was placed in sensitization buffer (0.04 M PO 4 [pH 7.2]).
Plates were incubated for a minimum of 3 hours at 37 C and then stored overnight at 4 C. The plates then were treated with 100 μL of methanol (−20 C) for 5 minutes before blocking for 60 minutes at 37 C with 120 μL of PBS + 1% skim milk (1 g/100 mL) that was heated to 65 C for 60 minutes to pasteurize the solution. All C1 deposition assays were performed in quadruplicate for each test plasma; results of replicates were included in mixed-effects regression modeling (described below in the Statistical Methods section). Samples of each plasma were heat inactivated (56 C for 30 minutes), and 50 μL of each plasma was combined with 50 μL of complement source (100 μL/well)
for 60 minutes on a rocker at 37 C. The purpose of heat treating the plasma was to inactivate complement in each plasma product such that, by using a common source of complement, innate differences among plasmas to deposit complement could not be attributed to innate differences in complement activity in the plasma products. After washing 3 times with PBS + 0.05% Tween, affinity-purified goat anti-complement C1q primary antibody (Cedarlane, Inc, Burlington, North Carolina) was placed in each well (100 μL/ well) at a dilution of 1:1000, and incubated for 60 minutes at room temperature (approximately 22 C). This was followed by 3 wash cycles with PBS + 0.05% Tween, after which an anti-goat IgG-alkaline phosphatase (AP) secondary antibody produced in rabbits (anti-goat IgG-AP, Sigma-Aldrich) was placed in each well at a dilution of 1:2000. Plates were incubated for 60 minutes at room temperature.
After another 3 wash cycles, the AP-enzymatic production of color was elicited using a 1 mg/mL of 4-nitrophenyl phosphate disodium salt hexahydrate in substrate buffer for 30 minutes at 37 C. The ODs for each plate were recorded at a wavelength of 450 nm. 
| Opsonophagocytic killing assay
| Statistical methods
Data were analyzed using mixed-effects linear regression to evaluate effects of plasma treatment on C1 deposition onto plates coated with PNAG or R. equi by ELISA. The absorbance was modeled as the outcome variable. Dependent variables were the dilution, treatment, and their interaction which were modeled as fixed effects, and horse identification modeled as a random effect. Multiple comparisons of pairwise differences among treatments within dilution and dilution within treatment were made using the method of Sidak. 17 To evaluate effects of plasma treatment on opsonic killing of R. equi when incubated with neutrophils (and complement), data were analyzed using mixed-effects linear regression. The dependent variable was the proportion of bacteria surviving; treatment was modeled as a fixed effect and horse was modeled as a random effect. The proportional survival (relative to bacteria in media only) was transformed using the log 10 function to meet distributional assumptions of the model. Multiple comparisons of pair-wise differences either among treatments within dilution or dilution within treatment were made using the method of Sidak. 17 Significance level for analysis was set at P < .05.
| RESULTS
The concentrations of IgG determined by ELISA in the SP, RE-HIP, and PNAG were 1462, 2333, and 2116 mg/dL, respectively. The OD at 450 nm was measured for C1 deposition on to PNAG-coated plates at dilutions ranging from 1:100 to 1:6400 for each plasma (Figure 1 ). The PNAG-HIP deposited significantly more C1 onto PNAG compared to RE-HIP and SP at dilutions of 1:100, 1:200, and 1:400 (P < .05). There were no statistically significant differences at any of the dilutions measured between RE-HIP and SP for deposition of C1 onto PNAG.
Because of limitations in the amount of binding of the R. equi bacteria to the wells, the OD for the C1 deposition on to R. equi-coated plates was measured at dilutions ranging from 1:10 to 1:640 for each plasma (Figure 2 ). The RE-HIP deposited significantly (P < .05) more C1 onto R. equi compared to PNAG-HIP and SP at dilutions of 1:10, 1:20, and 1:40; there were no significant differences at any of the dilutions evaluated between PNAG-HIP and SP for C1 deposition onto R. equi.
Using linear mixed-effects modeling, proportional survival of R. equi for the PMNs and complement alone (PMNC, 114.3%; 95% confidence interval [CI], 92.5%-136.2%) did not differ significantly from that of bacteria in media only. All 3 plasma treatments, however, yielded bacterial counts that were significantly (P < .05) lower than the media only or PMNC controls (Figure 3) . Moreover, the proportional survival by PNAG- 
15
Although the RE-HIP mediated somewhat more killing than SP, the difference was not significant. The IgG concentration of SP was approximately 70% of the IgG concentration in RE-HIP (and PNAG-HIP), but its concentration was similar to the reported ranges for commercially available plasmas. 20, 21 Although data are lacking from either observational studies or randomized controlled field trials, our findings are consistent with prior experimental evidence of similar survival among foals infected with R. equi that were transfused with RE-HIP or SP before infection. 22 Further evaluation of the comparison of SP and RE-HIP is warranted inasmuch as our study was limited to in vitro data and was underpowered to detect the observed magnitude of difference between these 2 plasma products.
Our study had a number of limitations. Results of this in vitro study do not provide evidence of superior protection of PNAG-HIP in vivo.
Nonetheless, we considered this in vitro study essential preliminary evidence to justify field-based comparisons among plasma products. The complement deposition assays indicated that both PNAG-HIP and RE-HIP deposited complement onto their targets, but PNAG-HIP was superior to RE-HIP in bacterial killing. This discrepancy suggests that the difference in OPK function is not the result of superior complement activation by anti-PNAG antibodies but rather might be because of the location of the opsonins on the surface of the bacteria. The mechanism of action of antibody to PNAG is an ongoing activity in our laboratory.
We did not evaluate the ability of PMNs from foals to mediate killing, and evidence exists that there are functional deficits in opsonic capacity and functional responses of neonatal foal PMNs. [23] [24] [25] [26] [27] [28] [29] [30] [31] We do note,
however, that active vaccination of pregnant mares with a PNAG conjugate vaccine as well as passive administration of PNAG-HIP to newborn foals resulted in an aggregate protection from R. equi intrabronchial challenge of 94%, whereas 91% of foals born to control mares in the active vaccine trial or foals receiving SP in the passive protection trial developed R. equi pneumonia. 15 The foals were 4 weeks of age at challenge, 15 and likely had functional phagocytes and complement at this point. At the time the study reported here was conducted, we did not have an opportunity to obtain PMNs from young foals. The sex and age distribution of our population was not ideal (8 mares and 1 gelding), but the similar functional responses of all horses suggest that this did not confound our results. Finally, our sample size was modest, and having more horses would have enhanced the precision and power of the study. Only a single strain of R. equi (1 for which we have in vitro and in vivo evidence of virulence) was considered in our study. Thus, our results cannot necessarily be extrapolated to other strains, but we have reported that 100% of R. equi clinical isolates tested produce surface PNAG antigen. 15 Although considerable genetic heterogeneity of R. equi strains has been reported, 32 there is no evidence of variation in virulence or response to plasma treatment among isolates of R. equi. It is generally considered that any isolate bearing the virulence-associated plasmid can cause disease in susceptible foals. 1 Despite these limitations, we found convincing evidence that PNAG-HIP mediated significantly more killing than did RE-HIP. The relevance of this finding merits further investigation in vivo. Further investigations of the mechanism of anti-PNAG antibodies to mediate protection against R. equi are warranted.
| CONCLUSIONS
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